Tag: HEA MTC PHA

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

On Demand Pharmaceuticals Welcomes HHS Leadership to Showcase Breakthrough Domestic Pharmaceutical Manufacturing Capabilities

ROCKVILLE, Md., Aug. 14, 2025 /PRNewswire/ -- Today, On Demand Pharmaceuticals (ODP) hosted senior officials from the U.S. Department of Health and Human Services...

Norgine completes acquisition of Theravia

PARIS, Aug. 14, 2025 /PRNewswire/ -- Norgine today announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specialising in therapies for...

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsHEA MTC PHA

The Bronx DC That Built Independent Grocery Is Getting a Major Upgrade

In HelloNation, Hearing Expert Allison Liberio Explains Hearing Aid Cost in Southlake, Texas

Boréal sets a new record as it celebrates more than 1,000 graduates at its 31st graduation ceremonies

Tag: HEA MTC PHA

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

On Demand Pharmaceuticals Welcomes HHS Leadership to Showcase Breakthrough Domestic Pharmaceutical Manufacturing Capabilities

Norgine completes acquisition of Theravia

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

Azitra, Inc. Announces Reverse Stock Split

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Philippines’ AC Health partners with Singapore’s ABC Impact in vision to transform health for every Filipino

Philippines’ AC Health partners with Singapore’s ABC Impact in vision to transform health for every Filipino

Philippines’ AC Health partners with Singapore’s ABC Impact in vision to transform health for every Filipino

Hugel launches botulinum toxin Letybo in Malaysia

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us